华北制药9月16日晚间公告，公司全资子公司深圳华药南方制药有限公司获得国家药品监督管理局核准 签发的注射用亚胺培南西司他丁钠（1.0g）《药品注册证书》。本品为亚胺培南和西司他丁钠组成的复 方制剂。本品适用于由敏感细菌所引起的下列感染：腹腔内感染、下呼吸道感染、妇科感染、败血症、 泌尿生殖道感染、骨关节感染、皮肤软组织感染、心内膜炎，本品适用于治疗由敏感的需氧菌/厌氧菌 株所引起的混合感染。截至目前，除原研产品外，包括南方公司在内，国内共有10家企业持有注射用亚 胺培南西司他丁钠（1.0g）的药品注册证书。 ...

证券代码：600812 证券简称：华北制药 编号：临 2025-048 华北制药股份有限公司 关于参加 2025 年河北辖区上市公司投资者网上集体接待 日暨 2025 年半年报集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于2025年9月14日（星期日）16:00前将需要了解和关注的问题通过电 子邮件的形式发送至公司邮箱：ncpcdshbgs@163.com。公司将在本次活动上对投资者普 遍关注的问题进行回答。 华北制药股份有限公司（以下简称"公司"）已于2025年8月14日在上 海证券交易所网站（www.sse.com.cn）披露了公司《2025年半年度报告》。 为进一步加强与投资者的互动交流，公司将参加由河北省上市公司协会与 深圳市全景网络有限公司联合举办的"2025年度河北辖区上市公司投资者 网上集体接待日暨2025年半年报集体业绩说明会"（以下简称"本次活动"）， 就投资者普遍关心的问题进行交流。 一、说明会类型 本次活动以网络互动形式召开，公司将就2025年半年度业绩、 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The company announced that it has signed guarantee contracts with China Construction Bank and China Everbright Bank to provide joint liability guarantees for its subsidiary, Huayao International Pharmaceutical Co., Ltd [2] - The maximum guarantee amounts are set at 30 million yuan and 150 million yuan respectively [2] - As of the date of the announcement, the total guarantee amount provided by the company to Huayao International is 230 million yuan, including the current guarantees [2]

Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating the product meets the basic entry requirements for centralized procurement and has equivalent efficacy to the original product [1] Group 1 - The injectable vancomycin hydrochloride is effective against infections caused by methicillin-resistant Staphylococcus aureus and other bacteria, including conditions such as sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical wound infections, pneumonia, lung abscess, empyema, peritonitis, and meningitis [1] - The product can also be administered orally for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and staphylococcal enterocolitis [1] - The approval of this product enhances the company's product structure in the field of anti-infection, building on its existing product, Vanxun (injectable desacetyl vancomycin) [1]

Group 1 - The total external guarantees provided by the company and its subsidiaries amount to approximately 1.656 billion yuan, which represents 30.72% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] - The company has provided guarantees totaling about 1.566 billion yuan for its subsidiaries, accounting for 29.05% of the audited net assets attributable to ordinary shareholders for 2024 [1] - The amount of guarantees for entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for 2024 [1] Group 2 - For the first half of 2025, the revenue composition of the company is as follows: chemical preparations account for 42.67%, chemical raw materials account for 25.02%, biological preparations account for 16.71%, pharmaceutical and other logistics trade account for 6.76%, and pharmaceutical intermediates account for 6.47% [1] - The current market capitalization of the company is 10.7 billion yuan [1]

Core Viewpoint - North China Pharmaceutical has received approval from the National Medical Products Administration for the injection of Vancomycin Hydrochloride (0.5g), with a validity period until August 25, 2030 [1] Group 1: Product Information - Vancomycin Hydrochloride primarily exerts its bactericidal effect by inhibiting the biosynthesis of the bacterial cell wall [1] - The drug can alter the permeability of bacterial cell membranes and RNA synthesis [1] - It is suitable for intravenous infusion for infections caused by Methicillin-resistant Staphylococcus aureus and other bacteria, and can be taken orally for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile, as well as Staphylococcal enterocolitis [1]

证券代码：600812 证券简称：华北制药 公告编号：临 2025-046 华北制药股份有限公司 关于为下属子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 本次担保金额 | 18,000 | 华药国际医药有限公司 万元 | | | --- | --- | --- | --- | --- | | 担保对象一 | 实际为其提供的担保余额 | 23,000 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | √否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 9,000 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 165,586.06 | | 对外担保总额占上市公司最近一 | 30.72 | | 期经审计净资产的比例（%） | | | | □对外担保总额超过最 ...

证券代码：600812 股票简称：华北制药 编号：临 2025-047 华北制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，华北制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的注射用盐酸万古霉素（0.5g）《药品注册证书》，现 将有关情况公告如下： | 药品名称 | | 药品通用名称：注射用盐酸万古霉素 | | | | --- | --- | --- | --- | --- | | | | 英文名/拉丁名：Vancomycin | Hydrochloride | for Injection | | 主要成分 | | 盐酸万古霉素 | | | | 剂 | 型 | 注射剂 | 申请事项 | 药品注册（境内生 产） | | 规 | 格 | 0.5g（50 万单位） （按 C66H75Cl2N9O24 计） | 注册分类 | 化学药品 4 类 | | 药品注册标准编号 | | YBH19752025 | 药品有效期 | 18 个月 | | 包装规格 | | 1 瓶/盒 | 处方药/非处方药 ...

Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating the product meets the basic entry requirements for centralized procurement and has equivalent efficacy to the original product [1] Group 1: Product Information - Injectable vancomycin hydrochloride primarily acts by inhibiting bacterial cell wall biosynthesis and can alter bacterial cell membrane permeability and RNA synthesis [1] - The intravenous administration is suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria, including conditions such as sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical wound infections, pneumonia, lung abscess, empyema, peritonitis, and meningitis [1] - The oral form is indicated for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and staphylococcal enterocolitis [1] Group 2: Market Position and Strategy - The approval of injectable vancomycin hydrochloride enhances the company's product portfolio in the anti-infection field, building on its existing product, Vanxun (injectable deacetyl vancomycin hydrochloride) [1] - This development is expected to effectively improve the company's competitive position in the market for anti-infection products [1]